



F. No. 01-02/2025-CPS(DRAP)  
Government of Pakistan  
Ministry of National Health Services, Regulation & Coordination  
**Drug Regulatory Authority of Pakistan**  
Prime Minister Health Complex, Park Road, Islamabad

\*\*\*\*\*

*Islamabad, the 3<sup>rd</sup> June 2025.*

**NOTIFICATION**

**Subject: PRIORITY PROCESSING OF CYSTEAMINE REGISTRATION APPLICATIONS**

In light of the current non-registration status of Cysteamine and to ensure its earliest possible availability, the Drug Regulatory Authority of Pakistan (DRAP) in its 205<sup>th</sup> meeting held on 29<sup>th</sup> May 2025 has designated Cysteamine as priority drug. All registration applications for Cysteamine will be processed on priority basis, out of queue, for a period of one (1) year from the date of issuance of this notification.

2. All relevant stakeholders are requested to acknowledge this decision of DRAP and proceed accordingly to facilitate the expedited processing and availability of Cysteamine in the market.

(Ahsan Ul-Haq Athar)

Deputy Director

Communication, Publication & Stakeholder Engagement

CEO-Secretariate

**Distribution: -**

1. PS to CEO-DRAP, Islamabad
2. Director (PE&R), DRAP, Islamabad.
3. Director (MIS), DRAP with request to upload on DRAP official website.
4. Chairman, Pakistan Pharmaceutical Manufacturer Association (PPMA), H.No.474, St.34 I-8/2 Islamabad
5. Executive Director, Pharma Bureau, Chamber of Commerce, Talpur Road, Karachi.
6. Pakistan Chemist and Druggist Association (PCDA), Suit No.504, 5<sup>th</sup> Floor, Mashriq Center, Block 14, Gulshan e Iqbal, Karachi.
7. Office File



F. No. 01-02/2025-CPS(DRAP)  
Government of Pakistan  
Ministry of National Health Services, Regulation & Coordination  
**Drug Regulatory Authority of Pakistan**  
Prime Minister Health Complex, Park Road, Islamabad

\*\*\*\*\*

*Islamabad, the 5<sup>th</sup> June 2025.*

**CORRIGENDUM**

Subject: **PRIORITY PROCESSING OF MEXILETINE REGISTRATION APPLICATIONS**

In partial modification of Authority's Notification of even number dated 27<sup>th</sup> May 2025, it is hereby informed that the Drug Regulatory Authority of Pakistan (DRAP) has extended the period for priority processing of registration applications for Mexiletine from six (6) months to one (1) year from the date of the original notification.

*(Signature)*  
(Ahsan Ul Haq Athar)

Deputy Director

Communication, Publication & Stakeholder Engagement  
CEO-Secretariat

**Distribution: -**

1. PS to CEO-DRAP, Islamabad
2. Director (PE&R), DRAP, Islamabad.
3. Director (MIS), DRAP with request to upload on DRAP official website.
4. Chairman, Pakistan Pharmaceutical Manufacturer Association (PPMA), H.No.474, St.34 I-8/2 Islamabad
5. Executive Director, Pharma Bureau, Chamber of Commerce, Talpur Road, Karachi.
6. Pakistan Chemist and Druggist Association (PCDA), Suit No.504, 5<sup>th</sup> Floor, Mashriq
7. Center, Block 14, Gulshan e Iqbal, Karachi.
8. Office File